Last update 01 Nov 2024
ISHIHARA SANGYO KAISHA LTD.

ISHIHARA SANGYO KAISHA LTD.

Public Company|
1949|
Osaka-fu, Japan
|
1,000-5,000
| TYO: 4028|

Overview

Tags

Neoplasms
Skin and Musculoskeletal Diseases
Urogenital Diseases
Oncolytic virus

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
no Data
No Data
Disease DomainCount
Neoplasms1
Top 5 Drug TypeCount
Oncolytic virus1

Corporation Tree

Boost your research with our corporation tree data.
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
1
8
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
GEN-0101
Mesothelioma
More
Phase 2
Tuberculosis vaccine(GenomIdea)
( IL-12 )
Tuberculosis
More
Discontinued
NSC-639829
( Tubulin )
Neoplasms
More
Discontinued
MT-2090
Rheumatoid Arthritis
More
Discontinued
MT-2221
Rheumatoid Arthritis
More
Discontinued
Login to view more data

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free